88 related articles for article (PubMed ID: 6542371)
41. Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
Bernengo MG; Fra P; Lisa F; Meregalli M; Zina G
Clin Immunol Immunopathol; 1983 Sep; 28(3):311-24. PubMed ID: 6603936
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant chemotherapy in high-risk malignant melanoma.
Karakousis CP; Emrich LJ
J Surg Oncol; 1987 Sep; 36(1):64-7. PubMed ID: 3306159
[TBL] [Abstract][Full Text] [Related]
43. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
[TBL] [Abstract][Full Text] [Related]
44. [Thymostimulin in the therapy of bronchiolitis: clinical evaluation in a controlled study].
Oggero R; Spinello M; Tovo PA; Salomone C; Magi MT
Pediatr Med Chir; 1986; 8(2):203-7. PubMed ID: 2431395
[TBL] [Abstract][Full Text] [Related]
45. A clinicopathologic study of amelanotic melanoma.
Huvos AG; Shah JP; Goldsmith HS
Surg Gynecol Obstet; 1972 Dec; 135(6):917-20. PubMed ID: 5086000
[No Abstract] [Full Text] [Related]
46. [The use of thymostimulin in lymphoma and myeloma patients].
Cánovas Fernández A; Alonso Alonso J; González de Zárate P; García Masdevall MD; Riñón Martínez-Gallo M; Aguirre Errasti C
An Med Interna; 1991 Feb; 8(2):69-73. PubMed ID: 1893006
[TBL] [Abstract][Full Text] [Related]
47. T-dependent immunity in aged humans. II. Clinical and immunological evaluation after three months of administering a thymic extract.
Pandolfi F; Quinti I; Montella F; Voci MC; Schipani A; Urasia G; Aiuti F
Thymus; 1983 Apr; 5(3-4):235-40. PubMed ID: 6410547
[TBL] [Abstract][Full Text] [Related]
48. Melanoma update.
Seyfer AE
West J Med; 1991 Feb; 154(2):204-5. PubMed ID: 2006571
[No Abstract] [Full Text] [Related]
49. Thymostimulin therapy in patients with measles meningoencephalitis.
Tovo PA; Pugliese A; Palomba E; Delpiano AM; Martino S; Incarbone E
Thymus; 1986; 8(1-2):91-4. PubMed ID: 3726944
[TBL] [Abstract][Full Text] [Related]
50. A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin's disease in complete remission.
Liberati AM; Ballatori E; Fizzotti M; Schippa M; Cini L; Cinieri S; Proietti MG; Di Marzio R; Senatore M; Grignani F
Cancer Immunol Immunother; 1988; 26(1):87-93. PubMed ID: 3125973
[TBL] [Abstract][Full Text] [Related]
51. [Practical treatment of malignant melanoma].
Körlof B
Nord Med; 1970 Oct; 84(42):1340-1. PubMed ID: 4991371
[No Abstract] [Full Text] [Related]
52. Randomized controlled trial of transfer factor in Stage II malignant melanoma.
Bukowski RM; Deodhar S; Hewlett JS; Greenstreet R
Cancer; 1983 Jan; 51(2):269-72. PubMed ID: 6336977
[TBL] [Abstract][Full Text] [Related]
53. [Considerations on the treatment of melanomas].
Pattavel J
Praxis; 1968 Oct; 57(39):1333-7. PubMed ID: 5756752
[No Abstract] [Full Text] [Related]
54. [Results of the surgical treatment of patients with primary melanoma of the skin].
Vagner RI; Anisimov VV
Khirurgiia (Mosk); 1987 Sep; (9):34-7. PubMed ID: 3695248
[No Abstract] [Full Text] [Related]
55. [Surgical treatment of malignant melanoma of the skin and our results].
Putnik M; Tomin R; Nikolić S
Srp Arh Celok Lek; 1966 Jan; 94(1):31-8. PubMed ID: 5984643
[No Abstract] [Full Text] [Related]
56. Use of a thymic factor in the prevention of postoperative infections.
Terrizzi A; Gipponi M; Meloni C; Farina PG; Pellas C; Berti Riboli E
Ital J Surg Sci; 1985; 15(3):243-8. PubMed ID: 4066275
[TBL] [Abstract][Full Text] [Related]
57. Controlled trial of a thymic hormone extract (Thymostimulin) in 'autoimmune' chronic active hepatitis.
Hegarty JE; Nouri Aria KT; Eddleston AL; Williams R
Gut; 1984 Mar; 25(3):279-83. PubMed ID: 6230296
[TBL] [Abstract][Full Text] [Related]
58. Beneficial effects of the thymic hormone preparation thymostimulin in patients with defects in cell-mediated immunity and chronic purulent rhinosinusitis. A double-blind cross-over trial on improvements in monocyte polarization and clinical effects.
Tas M; Leezenberg JA; Drexhage HA
Clin Exp Immunol; 1990 Jun; 80(3):304-13. PubMed ID: 2197046
[TBL] [Abstract][Full Text] [Related]
59. [Toxicologic studies with thymostimulin].
Leuschner F; Neumann W
Arzneimittelforschung; 1985; 35(5):836-8. PubMed ID: 3927927
[TBL] [Abstract][Full Text] [Related]
60. Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome.
Chachoua A; Green MD; Valentine F; Muggia FM
Cancer Invest; 1989; 7(3):225-9. PubMed ID: 2790539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
